JAN (NYSE:JAN) Upgraded by Jefferies Financial Group to “Strong-Buy” Rating

JAN (NYSE:JAN) was upgraded by investment analysts at Jefferies Financial Group to a “strong-buy” rating in a note issued to investors on Tuesday, Zacks reports.

JAN has been the subject of several other research reports. Compass Point began coverage on shares of JAN in a research report on Wednesday. They set a “neutral” rating and a $37.00 price objective for the company. Weiss Ratings assumed coverage on shares of JAN in a report on Thursday, August 6th. They issued a “hold (c-)” rating for the company. Raymond James Financial began coverage on shares of JAN in a research note on Tuesday, June 16th. They issued a “strong-buy” rating and a $34.00 price target for the company. Cantor Fitzgerald upped their price objective on shares of JAN from $30.00 to $34.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Finally, Zacks Research cut shares of JAN from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.31.

JAN Stock Performance

Shares of JAN stock opened at $30.52 on Tuesday. JAN has a one year low of $22.76 and a one year high of $32.83. The company’s 50-day simple moving average is $30.48.

JAN (NYSE:JAN) last issued its earnings results on Tuesday, August 4th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.18). The business had revenue of $216.46 million during the quarter, compared to analyst estimates of $203.32 million. The firm’s quarterly revenue was up 45.4% compared to the same quarter last year. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. Equities research analysts expect that JAN will post 0.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Engineers Gate Manager LP acquired a new position in shares of JAN during the second quarter valued at about $15,274,000. Wellington Management Group LLP acquired a new stake in shares of JAN in the 2nd quarter worth about $8,739,000. WINTON GROUP Ltd bought a new position in JAN in the 2nd quarter valued at about $2,985,000. Readystate Asset Management LP bought a new position in JAN in the 2nd quarter valued at about $1,724,000. Finally, Greenland Capital Management LP acquired a new position in JAN during the 2nd quarter valued at about $575,000. Institutional investors and hedge funds own 6.27% of the company’s stock.

More JAN News

Here are the key news stories impacting JAN this week:

• Positive Sentiment: Monthly dividend provides income support: JAN declared a monthly dividend of $0.0475 per share, equivalent to an annualized yield of approximately 1.8%. The upcoming payments are scheduled for October 28, November 23, and December 29, 2026. JAN dividend announcement
• Positive Sentiment: Revenue growth remains strong: JAN reported quarterly revenue of $216.46 million, up 45.4% year over year and above the $203.32 million analyst consensus. Full-year fiscal 2026 guidance calls for earnings per share of $0.95 to $0.98.
• Neutral Sentiment: Analyst target indicates limited near-term upside: Analysts assign JAN an average price target of $31.71, modestly above the recent trading level. This suggests some potential upside, but not a major revaluation catalyst. JAN receives average analyst price target
• Negative Sentiment: Latest earnings missed expectations: JAN reported earnings of $0.05 per share, falling short of the $0.23 consensus estimate by $0.18. The earnings miss is likely the most important pressure on the stock, despite the better-than-expected revenue and continued growth.
• Negative Sentiment: Upside is being weighed against execution risk: With shares trading near the 50-day moving average and the analyst target only modestly higher, investors may remain cautious until JAN demonstrates that it can convert its revenue growth into stronger profitability.

About JAN

JanOne Inc is a technology and life sciences company focused on addressing the global opioid crisis. The company’s activities include developing and supporting pharmaceutical and other solutions intended to help reduce opioid-related deaths and dependency.

JanOne has also pursued blockchain and financial technology initiatives through its Alt 5 Sigma operations. These activities have included blockchain-based payment, digital asset and financial services solutions designed to help businesses manage transactions and related digital assets.

The company serves markets through its healthcare, technology and financial services initiatives, with an emphasis on solutions that can be applied internationally.